Aerie Pharmaceuticals (AERI) Jumped To A New High On Phase 3 Study Results

Aerie Pharmaceuticals Inc. (AERI) announced after the bell Wednesday that its Phase 3 clinical trial of RoclatanTM achieved its primary efficacy endpoint. Roclatan is an investigational glaucoma drug.

from RTT - Before the Bell http://ift.tt/2cvNLs1
via IFTTT